Benefiting from their high brightness and ehanced targeting as well as NIR‐II emission property, upon intravenous injection, the NIR‐II Pdots‐GnRH display superior detection sensitivity during the imaging of ovarian cancer peritoneal metastases and lymphatic metastases. This evidence concerns the gene GNRH1 and ovarian cancer.